Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its PDUFA date, the agency approved the firm’s first-line breast cancer treatment ...

*Based on data released by the Federal Election Commission on October 17, 2024 except for independent expenditure and communication cost, contributions to federal candidates, and contributions from ...

Genentech, a member of the Roche (RHHBY), announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology, or ASH, annual meeting and ...

ADMINISTRATIVE: The operational costs of running a campaign or PAC, including travel expenses, office rent and supplies, utilities, equipment, food, meetings, and administrative services such as ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

Genentech Inc. will be cutting 436 jobs at its South San Francisco headquarters. Sanofi, which is headquartered in Paris, will also be cutting 100 jobs at its South SF office, according to notices ...

Roche Group unit Genentech said that the Food and Drug Administration approved Itovebi for treating certain breast cancer. The approval is for Itovebi in combination with palbociclib and ...

Spending $100,000 on a treatment program that is either entirely useless, or which will buy a brain-cancer patient a few extra weeks of life, would have been an irresponsible use of government ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented positive 2-year data from the ongoing RAINBOWFISH study at the 29th ...

RICHMOND, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial ...

Lineage Cell Therapeutics Inc (LCTX) extends its cash runway and progresses in key partnerships, despite facing regulatory ...